Kyowa Kirin Terminates its Agreement with Zeria Pharmaceuticals for ASACOL (mesalazine)
Kyowa Kirin Signs Two Agreement with Ardelyx to Expand its Existing Partnership
Shots:
- Kyowa will terminate its sales and marketing activities for ASACOL on Mar 31, 2020. Zeria to get exclusive full rights for sales and marketing for ASACOL from Apr 01, 2020
- In Jan 2007, Kyowa and Zeria signed an exclusive co-development and co-marketing agreement for ASACOL in Japan
- ASACOL (mesalazine) is an anti-inflammatory enteric-coated tablet involved in releasing active ingredient mesalazine pH dependently and was launched in Japan in Dec 2009, targeted to treat ulcerative colitis in Japan
Click here to read full press release/ article | Ref: Kyowa Kirin | Image: Pharma World